Compass says COMP360 regulatory review timeline accelerates
Compass Pathways says its regulatory review for COMP360 is accelerating, targeting end-2026 readiness and a H1 2027 commercial launch, and reports open-label data showing rapid, durable benefit in resistant depression; it also flags advance of its major PTSD program and other pipeline updates.